pramipexole has been researched along with ziprasidone in 4 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (ziprasidone) | Trials (ziprasidone) | Recent Studies (post-2010) (ziprasidone) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 1,068 | 254 | 362 |
| Protein | Taxonomy | pramipexole (IC50) | ziprasidone (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.005 | |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | 5.39 | |
| D | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.1514 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.1514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0004 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2301 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davidson, M; Levy, A; Weizer, M | 1 |
2 review(s) available for pramipexole and ziprasidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Pramipexole; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles | 1997 |
2 other study(ies) available for pramipexole and ziprasidone
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |